Zurück
realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" alt="" />
Top-News
Sunesis Pharmaceuticals könnte sehr interessant
Beiträge: 106
Zugriffe: 28.809 / Heute: 5
Zugriffe: 28.809 / Heute: 5
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +75,36%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +59,57%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +37,65%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +37,47%
finance.yahoo.com/q?s=SNSS
www.finanznachrichten.de/...aktien/sunesis-pharmaceuticals.asp
www.finanznachrichten.de/...aktien/sunesis-pharmaceuticals.asp
bin ja seit jahren mehr auf wallstreet online unterwegs...
aber in jeder aktie, die ich seit 1 woche im biotech bereich hier auf ariva
"abgrase" finde ich dich...muss dich auf meine watchlist setzen -
du scheinst ein echt gutes "gespür" zu haben...!!!
bin nach Repros Th. gestern abend zu $ 0,53 hier rein...AH sehr stark!
we will see!
aber in jeder aktie, die ich seit 1 woche im biotech bereich hier auf ariva
"abgrase" finde ich dich...muss dich auf meine watchlist setzen -
du scheinst ein echt gutes "gespür" zu haben...!!!
bin nach Repros Th. gestern abend zu $ 0,53 hier rein...AH sehr stark!
we will see!
anstieg hoffentlich mit guten nachrichten! suche schon mal
ir.sunesis.com/...ol-newsArticle&ID=1678333&highlight=
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement
Design and Execution of VALOR Trial Enable Innovative Financing
SOUTH SAN FRANCISCO, Calif., March 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (Nasdaq:SNSS) and Royalty Pharma today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis' lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
Image: Sunesis Pharmaceuticals, Inc. Logo
Image: Royalty Pharma Logo
Sunesis is evaluating vosaroxin in a pivotal Phase 3, randomized, double-blind, placebo-controlled trial, the VALOR trial, in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial employs an adaptive trial design that permits a one-time increase in sample size at the interim analysis by its Data and Safety Monitoring Board (DSMB). At the interim analysis, expected in the third quarter of 2012, the DSMB will examine pre-specified efficacy and safety data sets and decide whether to stop the study early for efficacy or futility, continue the study as planned or implement a one-time sample size adjustment of 225 additional evaluable patients.
Under terms of the agreement, Royalty Pharma will invest $25 million immediately following VALOR's interim analysis if: (a) the study stops early for efficacy, in exchange for a 3.6% participation payment on future net sales; or (b) the one-time sample size increase is being implemented, in exchange for a 6.75% participation payment on future net sales as well as two warrants. In the case when VALOR proceeds to its planned 450 patient enrollment, Royalty Pharma has the option to make a $25 million investment upon the unblinding of the study in exchange for a 3.6% participation payment on future net sales. The warrants issued to Royalty Pharma are exercisable if VALOR's sample size is increased and are each to purchase 1,000,000 shares of Sunesis common stock at an exercise price of $3.48 and $4.64 per share, respectively. Sunesis currently holds all worldwide commercial rights to its vosaroxin product.
"Royalty Pharma has a strong track record of identifying significant commercial opportunities in the pharmaceutical sector. We believe this commitment by Royalty Pharma is a validation of vosaroxin's potential in AML and reflects the significant upside of a positive VALOR trial," stated Daniel Swisher, Chief Executive Officer of Sunesis.
"This innovative transaction will provide us with access to added capital that extends our runway beyond the unblinding of VALOR and enables our team to actively prepare for vosaroxin's regulatory filings and US commercial launch. It will also allow us to selectively expand our development program and enhance our strategic flexibility on the timing and terms of vosaroxin partnering arrangements outside the US," added Eric Bjerkholt, Executive Vice President, Corporate Development & Finance of Sunesis.
"Sunesis' use of an adaptive trial design offers us an opportunity to invest in this promising biopharmaceutical product candidate on terms that are a win-win for both Sunesis and Royalty Pharma: Sunesis gains access to a flexible, novel financing structure and we are able to invest in vosaroxin at a time when we believe its likelihood of commercial success will be high," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Based on our extensive due diligence, we are impressed with the Sunesis team, the robust preclinical and clinical dataset for vosaroxin, as well as the rigor of the VALOR trial design and implementation. We are pleased to be partnering with Sunesis in this transaction, and believe that this first-in-class compound has the potential to transform the treatment landscape for AML and potentially other cancers."
About VALOR
VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed or refractory AML. The trial is expected to enroll 450 evaluable patients at more than 110 leading sites in the U.S., Canada, Europe, Australia and New Zealand. The VALOR trial is currently enrolling patients, who are randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine daily for five days, or placebo in combination with cytarabine. Additionally, the VALOR trial employs an innovative, adaptive trial design that allows for a one-time sample size adjustment by the DSMB at the interim analysis to maintain adequate power across a broader range of survival outcomes. The trial's primary endpoint is overall survival. For more information on the VALOR trial, please visit www.valortrial.com.
About Vosaroxin
Vosaroxin is a first-in-class anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis..............................
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement
Design and Execution of VALOR Trial Enable Innovative Financing
SOUTH SAN FRANCISCO, Calif., March 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (Nasdaq:SNSS) and Royalty Pharma today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis' lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
Image: Sunesis Pharmaceuticals, Inc. Logo
Image: Royalty Pharma Logo
Sunesis is evaluating vosaroxin in a pivotal Phase 3, randomized, double-blind, placebo-controlled trial, the VALOR trial, in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial employs an adaptive trial design that permits a one-time increase in sample size at the interim analysis by its Data and Safety Monitoring Board (DSMB). At the interim analysis, expected in the third quarter of 2012, the DSMB will examine pre-specified efficacy and safety data sets and decide whether to stop the study early for efficacy or futility, continue the study as planned or implement a one-time sample size adjustment of 225 additional evaluable patients.
Under terms of the agreement, Royalty Pharma will invest $25 million immediately following VALOR's interim analysis if: (a) the study stops early for efficacy, in exchange for a 3.6% participation payment on future net sales; or (b) the one-time sample size increase is being implemented, in exchange for a 6.75% participation payment on future net sales as well as two warrants. In the case when VALOR proceeds to its planned 450 patient enrollment, Royalty Pharma has the option to make a $25 million investment upon the unblinding of the study in exchange for a 3.6% participation payment on future net sales. The warrants issued to Royalty Pharma are exercisable if VALOR's sample size is increased and are each to purchase 1,000,000 shares of Sunesis common stock at an exercise price of $3.48 and $4.64 per share, respectively. Sunesis currently holds all worldwide commercial rights to its vosaroxin product.
"Royalty Pharma has a strong track record of identifying significant commercial opportunities in the pharmaceutical sector. We believe this commitment by Royalty Pharma is a validation of vosaroxin's potential in AML and reflects the significant upside of a positive VALOR trial," stated Daniel Swisher, Chief Executive Officer of Sunesis.
"This innovative transaction will provide us with access to added capital that extends our runway beyond the unblinding of VALOR and enables our team to actively prepare for vosaroxin's regulatory filings and US commercial launch. It will also allow us to selectively expand our development program and enhance our strategic flexibility on the timing and terms of vosaroxin partnering arrangements outside the US," added Eric Bjerkholt, Executive Vice President, Corporate Development & Finance of Sunesis.
"Sunesis' use of an adaptive trial design offers us an opportunity to invest in this promising biopharmaceutical product candidate on terms that are a win-win for both Sunesis and Royalty Pharma: Sunesis gains access to a flexible, novel financing structure and we are able to invest in vosaroxin at a time when we believe its likelihood of commercial success will be high," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Based on our extensive due diligence, we are impressed with the Sunesis team, the robust preclinical and clinical dataset for vosaroxin, as well as the rigor of the VALOR trial design and implementation. We are pleased to be partnering with Sunesis in this transaction, and believe that this first-in-class compound has the potential to transform the treatment landscape for AML and potentially other cancers."
About VALOR
VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed or refractory AML. The trial is expected to enroll 450 evaluable patients at more than 110 leading sites in the U.S., Canada, Europe, Australia and New Zealand. The VALOR trial is currently enrolling patients, who are randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine daily for five days, or placebo in combination with cytarabine. Additionally, the VALOR trial employs an innovative, adaptive trial design that allows for a one-time sample size adjustment by the DSMB at the interim analysis to maintain adequate power across a broader range of survival outcomes. The trial's primary endpoint is overall survival. For more information on the VALOR trial, please visit www.valortrial.com.
About Vosaroxin
Vosaroxin is a first-in-class anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis..............................
erst wenn ichs sehe, trotzdem.... : ))
http://www.ariva.de/news/...steinschaetzung-Cantor-Fitzgerald-4071364
Cantor Fitzgerald - Sunesis Pharmaceuticals-Aktie: Ersteinschätzung
08:13 16.04.12
New York (www.aktiencheck.de) - Die Analysten von Cantor Fitzgerald stufen die Aktie von Sunesis Pharmaceuticals (SUNESIS PHARMACEUTICALS Aktie) in einer Ersteinschätzung mit dem Rating "buy" ein. Das Kursziel sehe man bei 6,00 USD. (Analyse vom 13.04.2012) (16.04.2012/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
http://www.ariva.de/news/...steinschaetzung-Cantor-Fitzgerald-4071364
Cantor Fitzgerald - Sunesis Pharmaceuticals-Aktie: Ersteinschätzung
08:13 16.04.12
New York (www.aktiencheck.de) - Die Analysten von Cantor Fitzgerald stufen die Aktie von Sunesis Pharmaceuticals (SUNESIS PHARMACEUTICALS Aktie) in einer Ersteinschätzung mit dem Rating "buy" ein. Das Kursziel sehe man bei 6,00 USD. (Analyse vom 13.04.2012) (16.04.2012/ac/a/a)
Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Denn lass dich mal positiv in der nächsten Zeit überraschen, die die Veröffentlichung der Phase 3 Daten kommt immer näher...
Kurse um 4,5 - 5,5 $ werden im Vorfeld voraussichtlich erreicht, wenn man sich mal vergleichbare Firmen/Medikament anschaut...
Mal gucken, was heute bekannt gegeben wird...
Kurse um 4,5 - 5,5 $ werden im Vorfeld voraussichtlich erreicht, wenn man sich mal vergleichbare Firmen/Medikament anschaut...
Mal gucken, was heute bekannt gegeben wird...
wohl noch ein bischen. Wann ungefähr kommen denn die Daten von Phase 3.
Weiß das jemand?
Weiß das jemand?
Es wurde doch nichts neues veröffentlicht - oder habe ich gepennt?
auf den yahoo boards weiß keiner etwas, ich erwarte die Daten heute in der Vorbörse gegen 13.30Uhr, mal schauen.
ich habe so ein Spielchen schon öfters bei Bios gesehen, hier wollen noch ein paar große Ju
ngs rein...
ngs rein...
Sunesis Pharmaceuticals to Implement One-Time Sample Size Increase to Phase 3 VALOR Trial in AML
Sep 11, 2012 (GlobeNewswire via COMTEX) --
DSMB Recommends Increase Following Single, Pre-Planned Interim Efficacy
and Safety Analysis of VALOR; Enrollment Completion Expected in 2013
DSMB Recommendation Triggers $25.0 Million Investment in Sunesis from
Royalty Pharma
Sunesis to Host Conference Call Today at 9:00 AM Eastern Time
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. SNSS-22.35% today announced that it will implement a one-time, 225-patient sample size increase to its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML), bringing target enrollment to 675 patients. This is in response to the recommendation of the trial's independent Data and Safety Monitoring Board (DSMB) following their completion yesterday of a single, pre-planned interim analysis of unblinded efficacy and safety data sets from VALOR.
VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in patients with first relapsed or refractory AML. The pre-planned sample size increase of 225 additional patients is designed to maintain adequate statistical power over a broader range of survival outcomes. With the revised target sample size of 675 patients, Sunesis anticipates full enrollment of VALOR in 2013, with unblinding of the trial expected in the first half of 2014 upon reaching 562 events and final database lock. The DSMB recommendation also triggers Royalty Pharma's obligation to invest $25.0 million in Sunesis.
"The completion of VALOR's interim analysis is an important milestone for Sunesis," said Daniel Swisher, Chief Executive Officer of Sunesis. "In light of the design of VALOR, the DSMB's recommendation that we implement a one-time, 225-patient sample size increase is a promising development. We thank the DSMB for their comprehensive analysis, and trial investigators for their continued support of VALOR, which has now enrolled 412 patients. Importantly, we are pleased that we have committed funding that will allow us to implement this enrollment expansion and complete the pivotal trial in AML."
Sunesis' management and staff, VALOR clinical investigators, including members of the Study Steering Committee, and Royalty Pharma remain blinded to the interim trial data and analysis.
Royalty Pharma's $25.0 million investment is made pursuant to the terms of an agreement with Sunesis announced March 29, 2012. In exchange for their investment, Royalty Pharma will receive a 6.75% royalty on future net sales of vosaroxin and warrants to purchase Sunesis common stock.
Sep 11, 2012 (GlobeNewswire via COMTEX) --
DSMB Recommends Increase Following Single, Pre-Planned Interim Efficacy
and Safety Analysis of VALOR; Enrollment Completion Expected in 2013
DSMB Recommendation Triggers $25.0 Million Investment in Sunesis from
Royalty Pharma
Sunesis to Host Conference Call Today at 9:00 AM Eastern Time
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. SNSS-22.35% today announced that it will implement a one-time, 225-patient sample size increase to its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML), bringing target enrollment to 675 patients. This is in response to the recommendation of the trial's independent Data and Safety Monitoring Board (DSMB) following their completion yesterday of a single, pre-planned interim analysis of unblinded efficacy and safety data sets from VALOR.
VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in patients with first relapsed or refractory AML. The pre-planned sample size increase of 225 additional patients is designed to maintain adequate statistical power over a broader range of survival outcomes. With the revised target sample size of 675 patients, Sunesis anticipates full enrollment of VALOR in 2013, with unblinding of the trial expected in the first half of 2014 upon reaching 562 events and final database lock. The DSMB recommendation also triggers Royalty Pharma's obligation to invest $25.0 million in Sunesis.
"The completion of VALOR's interim analysis is an important milestone for Sunesis," said Daniel Swisher, Chief Executive Officer of Sunesis. "In light of the design of VALOR, the DSMB's recommendation that we implement a one-time, 225-patient sample size increase is a promising development. We thank the DSMB for their comprehensive analysis, and trial investigators for their continued support of VALOR, which has now enrolled 412 patients. Importantly, we are pleased that we have committed funding that will allow us to implement this enrollment expansion and complete the pivotal trial in AML."
Sunesis' management and staff, VALOR clinical investigators, including members of the Study Steering Committee, and Royalty Pharma remain blinded to the interim trial data and analysis.
Royalty Pharma's $25.0 million investment is made pursuant to the terms of an agreement with Sunesis announced March 29, 2012. In exchange for their investment, Royalty Pharma will receive a 6.75% royalty on future net sales of vosaroxin and warrants to purchase Sunesis common stock.
Mich wundert es trotzdem sehr dass hier nicht mehr passiert.
Sind diese News nicht wirklich richtig positive?
Gibt es hier ein paar gedanken eurer seits???
Vielen Dank.
www.pazzosognofinanza.com/...fici&op=dettaglio&id=5649
Im dezember gabs nen price target 2,3$ von roth capital,nun 4 monate später auf 4,3 erhöht.
|
Neueste Beiträge aus dem Viracta Therapeutics Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
8 | 105 | Sunesis Pharmaceuticals könnte sehr interessant | Mme.Eugenie | Mme.Eugenie | 05.07.22 22:02 | |
| 12 | Viracta Therapeutics, Inc. (VIRX) gute Aussichten | alpenland | Balu4u | 29.03.22 21:19 | ||
| 18 | Sunesis Pharmaceuticals | Tiger | Tiger | 11.08.20 13:35 |
